AR065910A1 - Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b - Google Patents

Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b

Info

Publication number
AR065910A1
AR065910A1 ARP080101363A ARP080101363A AR065910A1 AR 065910 A1 AR065910 A1 AR 065910A1 AR P080101363 A ARP080101363 A AR P080101363A AR P080101363 A ARP080101363 A AR P080101363A AR 065910 A1 AR065910 A1 AR 065910A1
Authority
AR
Argentina
Prior art keywords
methods
antagonists
rheumatoid arthritis
biological markers
forecast
Prior art date
Application number
ARP080101363A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR065910A1 publication Critical patent/AR065910A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
    • G06Q30/0217—Discounts or incentives, e.g. coupons or rebates involving input on products or services in exchange for incentives or rewards
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Se brindan los métodos y ensayos que analizan la expresion de uno o más marcadores biologicos en una muestra para predecir o indicar la efectividad del tratamiento de un paciente con artritis reumatoide (AR) con un antagonista de linfocitos B. Sebrindan los métodos para identificar los pacientes con posibilidades de que la AR responda a la terapia anti-AR utilizando un antagonista de linfocitos B. Además, se brindan los métodos para tratar dichos pacientes con antagonistas de linfocitos Bque consta de administrar al paciente un antagonista de linfocito B, a condicion de que se observe polimorfismo de nucleotido simple SNP (PTPN22) R620W, epitope compartido o ambos. Finalmente, se brindan los conjuntos y elementos de fabricacion queson utiles para dichos métodos.
ARP080101363A 2007-04-02 2008-04-01 Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b AR065910A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90969307P 2007-04-02 2007-04-02
US90992107P 2007-04-03 2007-04-03

Publications (1)

Publication Number Publication Date
AR065910A1 true AR065910A1 (es) 2009-07-08

Family

ID=39645462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101363A AR065910A1 (es) 2007-04-02 2008-04-01 Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b

Country Status (11)

Country Link
US (1) US20090204489A1 (es)
EP (1) EP2137325A1 (es)
JP (1) JP2010527325A (es)
CN (1) CN101711286A (es)
AR (1) AR065910A1 (es)
AU (1) AU2008232506A1 (es)
CA (1) CA2682406A1 (es)
CL (1) CL2008000948A1 (es)
MX (1) MX2009010620A (es)
TW (1) TW200902725A (es)
WO (1) WO2008122007A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
SI2298815T1 (sl) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
GB0803107D0 (en) * 2008-02-20 2008-03-26 Axis Shield Diagnostics Ltd Method
MX340204B (es) * 2008-04-11 2016-06-30 Emergent Product Dev Seattle Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2343372B1 (en) * 2008-10-03 2014-11-26 Kaytee Bio Co. & Ltd. Method for predicting pharmacological efficacy of anti-tnf antibody preparation on rheumatoid arthritis, and pharmacological efficacy prediction apparatus
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010139714A1 (en) * 2009-06-05 2010-12-09 F. Hoffmann-La Roche Ag Methods and systems for response detection and efficacy
ES2351456B1 (es) * 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
KR20120104517A (ko) * 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
EP2566973A4 (en) * 2010-05-04 2013-11-27 Medimmune Llc OPTIMIZED DIAGNOSIS AND TREATMENT OF MUSCLE DISTORTIONS
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
SG11201501595YA (en) * 2012-09-20 2015-05-28 Morphosys Ag Treatment for rheumatoid arthritis
HU230680B1 (hu) * 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
US20150220868A1 (en) * 2014-02-03 2015-08-06 Patient Profiles, LLC Evaluating Data Quality of Clinical Trials
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN205301177U (zh) * 2015-12-31 2016-06-08 深圳市贝沃德克生物技术研究院有限公司 家用肺炎支原体感染检测系统
CN108300779A (zh) * 2018-02-05 2018-07-20 广州和康医疗技术有限公司 一种用于预测来氟米特药物疗效的snp位点的试剂盒和方法
CN110426516A (zh) * 2019-04-11 2019-11-08 中国医学科学院肿瘤医院 辅助鉴定Rituximab耐药型ABC-DLBCL细胞的蛋白标志物及其应用
IT201900011151A1 (it) * 2019-07-08 2021-01-08 Gek S R L Metodo predittivo dell’efficacia di un trattamento con anticorpi antiCD20
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642596A3 (en) * 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EP1645291A1 (en) * 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
EP1881081A1 (en) * 2006-07-20 2008-01-23 Innogenetics N.V. Combinations of markers for increased accuracy of diagnosis of rheumatoid arthritis

Also Published As

Publication number Publication date
JP2010527325A (ja) 2010-08-12
CA2682406A1 (en) 2008-10-09
WO2008122007A1 (en) 2008-10-09
TW200902725A (en) 2009-01-16
US20090204489A1 (en) 2009-08-13
MX2009010620A (es) 2009-11-25
CN101711286A (zh) 2010-05-19
CL2008000948A1 (es) 2008-10-10
EP2137325A1 (en) 2009-12-30
AU2008232506A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
AR065910A1 (es) Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
BR112014012101A2 (pt) métodos de tratamento de artrite psoriática (psa) usando os antagonistas de il- 17 e alelos de resposta ou não resposta à psa
MX353186B (es) Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
BR112014011127A2 (pt) métodos para tratar, diagnosticar e monitorar doença de alzheimer
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
MX350010B (es) Inhibidores syk de imidazopiridinas.
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
NO20065907L (no) Nye tetrahydropyridotiofener
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
BR112012007555A2 (pt) biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
UY32521A (es) Combinación para emplear en el tratamiento de enfermedades respiratorias
ECSP11011472A (es) Antagonistas ccr3 arilsulfonamida 2, 5- disustituídos
AR097489A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica

Legal Events

Date Code Title Description
FB Suspension of granting procedure